We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Virus Avoids Antiviral Defenses by Co-opting Immune Protein
News

Virus Avoids Antiviral Defenses by Co-opting Immune Protein

Virus Avoids Antiviral Defenses by Co-opting Immune Protein
News

Virus Avoids Antiviral Defenses by Co-opting Immune Protein

Credit: Pixabay.
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Virus Avoids Antiviral Defenses by Co-opting Immune Protein "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

By discovering a trick the hepatitis C virus uses to evade the immune system, scientists have identified a new antiviral defence system that could be used to treat many virus infections, according to new research published today in eLife.

Viruses have many strategies to avoid immune system defenses. They often do this by hijacking the immune system’s own proteins. One immune protein that is frequently targeted by viruses, including HIV, hepatitis C, and the SARS coronavirus, is called cyclophilin A (CypA). Understanding how CypA is used by viruses could help scientists develop drugs that work against all of them, including the SARS-CoV-2 virus causing the COVID-19 pandemic.


“Previously, clinical trials have shown that blocking CypA reduces the ability of the hepatitis C virus to replicate and boosts the immune response,” explains lead author Che Colpitts, Assistant Professor of Biomedical and Molecular Sciences at Queen’s University, Kingston, Canada. “We set out to understand how CypA helps hepatitis C evade the immune system.”


In the experiments, the team used hepatitis C-infected human liver cancer cells with and without a functioning innate immune system. The innate immune system scans the body for potential threats such as viruses or bacteria and triggers a response. The scientists used a tool called a short hairpin RNA to selectively silence CypA and found that this stopped the virus from replicating only in the liver cells with a functioning innate immune system. They also showed that drugs called cyclophilin inhibitors help block the virus from co-opting CypA and prevent it from multiplying.


“CypA is known to attach to an immune protein called protein kinase R (PKR), affecting its ability to detect viruses. So, the team used a gene-editing tool called CRISPR/Cas9 to cut out the gene for PKR in human liver cells with a working innate immune system. In cells without PKR, the cyclophilin inhibitors were less able to stop the virus from reproducing. This happened because PKR was not there to identify the virus and trigger antiviral defenses.


“These findings reveal a new antiviral defence mechanism that suppresses virus growth,” says senior author Greg Towers, Professor of Molecular Virology at University College London, UK. “This opens the door for the development of CypA-targeting antiviral drugs that can be used against many currently untreatable viruses.”

Reference
Hepatitis C virus exploits cyclophilin A to evade PKR. Che C Colpitts, Sophie Ridewood, Bethany Schneiderman, Justin Warne, Keisuke Tabata, Caitlin F Ng, Ralf Bartenschlager, David L Selwood, Greg J Towers. eLife 2020;9:e52237 DOI: 10.7554/eLife.52237.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement